JAMA Study Demonstrates Efficacy of Life Technologies' Lung Cancer Test in Detecting Early Metastases, Supports Screening for

  JAMA Study Demonstrates Efficacy of Life Technologies' Lung Cancer Test in
        Detecting Early Metastases, Supports Screening for Lung Cancer

-Genetic test identifies patients at high risk for mortality in the earliest
stage of lung cancer

-Study suggests test could maximize the benefits of early screening if used in
combination with computed tomography

-Pervenio™ Lung RS test is available through Life Technologies' CLIA
Laboratory Developed Test Service

PR Newswire

CARLSBAD, Calif., Nov. 8, 2012

CARLSBAD, Calif., Nov. 8, 2012 /PRNewswire/ --Life Technologies Corporation
(NASDAQ:LIFE) today announced publication in the Journal of the American
Medical Association^1 (JAMA) of a study that underscores the clinical utility
of the company's early stage lung cancer test, Pervenio™ Lung RS. Launched in
September 2012, the genetic test has now been demonstrated to reliably
identify patients who are at high risk for mortality following surgery even
for the earliest stage of lung cancer.

The test was initially validated through two independent, blinded
retrospective studies involving approximately 1,500 patients, which were
published in the March 2012 issue of The Lancet.^2 The new study reports data
from a subset of patients included in the larger validation studies.
Specifically, it looks at those patients with "T1a, node-negative" tumors,
cancers that are smaller than two centimeters in diameter and that have no
detectable spread of the disease.

"We know that roughly a quarter of patients with T1a, node negative tumors
will die within five years, most often with recurrent lung cancer," said
Michael Mann, M.D., senior author of the study. "And yet these patients do not
receive any chemotherapy following surgery because there are no guidelines for
identifying which T1a patients are at high risk for mortality."

Dr. Mann is associate professor of cardiothoracic surgery at the University of
California, San Francisco and was involved in the development of the
Pervenio^TM Lung RS test along with co-author David Jablons, M.D., chief of
general thoracic surgery at the University of California, San Francisco.

"By the time the disease recurrence can be detected, it is too late for
therapies to be curative," said Dr. Jablons. "We know from previous clinical
trials that chemotherapy can cure metastatic lung cancer when it is treated
even before it can be detected. Therefore, we need to identify the high-risk
patients earlier, immediately after surgery if possible. Current published
guidelines already recommend consideration of chemotherapy at that time even
for stage I patients who are believed to be at the highest risk."

Pervenio™ Lung RS is a genetic test that examines activity of 14 genes in
tumor tissue. The current JAMA study demonstrates that the test accurately
predicted mortality risk among 269 T1a, node-negative patients. The test
categorized 92 patients as high risk; survival among these patients was just
over 50 percent. In contrast, survival among patients classified by the test
as low risk was nearly 85 percent. Further, when patients with tumors smaller
than one centimeter were examined, 100 percent of the low-risk patients
survived, as compared to just over 30 percent of the patients determined to be
at high risk by the test.

"Physicians don't need to send these early stage patients home for 'watchful
waiting' anymore, knowing that a good percentage of them will see their cancer
recur and many of those will die," said Ronnie Andrews, president of Medical
Sciences at Life Technologies. "We haven't seen survival rates for early stage
lung cancer improve significantly during the past 30 years, but now we have a
tool that can help enable more patients to receive a treatment that may
increase their survival closer to what we see in diseases in which we have
made progress, such as breast and colon cancer."

Five-year survival rates for stage I lung cancer are approximately 60
percent.By comparison, patients with stage I colon or breast cancer can
expect surgical cure rates of greater than 90 percent. In addition, genetic
testing of tumors may play a role in extending early screening efforts.

"Currently, the issue of screening for lung cancer is somewhat controversial,"
said Dr. Mann. "One challenge of screening is how to maximize the chances of
survival for a dramatically increased number of patients who would be
diagnosed at the very earliest stages. Right now, a quarter or more of those
patients would still die, despite early detection. The Pervenio™ test could
add a layer of sophistication and personalization to the care of that growing
population that could improve survival rates even further."

"There is also a movement toward limiting the loss of healthy lung tissue to
lung cancer operations," Dr. Jablons added, "but there is concern that
important prognostic information currently used in conventional staging might
be lost with less radical surgery. Pervenio™ has been shown to provide even
more accurate information about prognosis and would therefore enable equal or
even better clinical management decisions with lung-sparing operations."

Pervenio™ Lung RS is available through the  Life Technologies' Clinical
Services Lab, which is licensed in all 50 U.S. states. Life Technologies also
plans to make Pervenio™ Lung RS available outside of the United States, so the
test can be broadly deployed on Life Technologies' regulated platforms,
including the 7500 Fast Dx for qPCR.

The study, titled "Ability of a Prognostic Assay to Identify Patients at High
Risk of Mortality Despite Small, Node-Negative Lung Tumors," was supported by
private endowments to the UCSF Thoracic Oncology Laboratory and by Pinpoint
Genomics, which Life Technologies acquired in July 2012.

For more information, please visit www.lifelabdx.com. To order Pervenio™ Lung
RS, call the Life Technologies Clinical Services Lab at 1-888-734-8588

^1JAMA, Vol. 308 No. 16, pp. 1629-1631, October 24, 2012.
^2The Lancet, Vol. 379 No. 9818, pp. 823-832, Mar 03, 2012.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied Biosystems®,
Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life
Technologies employs approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of $3.7 billion in 2011. Visit us at our website:

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties.Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made byLife Technologies with the Securities and Exchange
Commission.Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Suzanne Clancy
858-205-4235 (mobile)

SOURCE Life Technologies Corporation

Website: http://www.lifetechnologies.com/
Press spacebar to pause and continue. Press esc to stop.